HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $48 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Halozyme Therapeutics (NASDAQ:HALO) and maintained a $48 price target on the stock.
January 19, 2024 | 11:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Mitchell Kapoor reaffirmed a Buy rating on Halozyme Therapeutics with a $48 price target, indicating a positive outlook for the stock.
The reiteration of a Buy rating and the maintenance of a $48 price target by a reputable analyst could lead to increased investor confidence in Halozyme Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100